This symposium is not accredited.

Special Announcement:

This symposium will precede the CCMG-CCGM Annual Scientific Meeting program and requires pre-registration, though CCMG-CCGM registrants will be able to attend at no additional cost. Moreover, we are pleased to offer a catered lunch, allowing for further networking and discussion in a relaxed setting.

This event is not just an opportunity to learn; it’s an invitation to be part of a pioneering community that is setting new standards in the diagnosis and treatment of rare diseases through the application of DNA methylation episignatures. Whether you manage a laboratory, lead a clinical program, or are involved in patient care, this workshop will provide valuable insights and practical applications that can enhance your work.

Register Here for this event

This comprehensive session will feature international experts who have hands-on experience managing laboratories and clinical programs that utilize episignature testing in patient care. These leaders in the field will share their insights, methodologies, and the impactful results of their work, offering attendees a unique opportunity to learn from those who are actively shaping the future of genetic diagnosis. Our international panel of experts includes:

  • Dr. Jill Fahrner, John’s Hopkins University
  • Dr. Matt Tedder, Greenwood Genetics Centre
  • Dr. Marielle Alders, Amsterdam University Medical Centre
  • Dr. Slavica Trajkova, University of Turin

Symposium Highlights:

  • Real-World Applications: Through detailed clinical case presentations, our speakers will illustrate various clinical and patient care scenarios. These narratives will showcase the real-world applications of DNA methylation episignatures, providing insights into their transformative potential in diagnosing rare diseases.
  • EpiSign-CAN National Clinical Trial: A special segment of the symposium will be dedicated to presenting the findings of the groundbreaking national clinical trial, “EpiSign-CAN: Beyond Genomics: Assessing the Improvement in Diagnosis of Rare Diseases Using Clinical Epigenomics in Canada.” This session will summarize the trial’s objectives, methodologies, and key outcomes, emphasizing the trial’s significant contributions to advancing our understanding and application of clinical epigenomics in Canada.
  • Networking Opportunities: Engage with peers, meet the experts, and exchange ideas during the workshop. This is your chance to connect with other professionals passionate about the potential of genetic and epigenomic research in improving patient outcomes.

Event Timeslots (1)

Day 1
-
Not accredited